446 related articles for article (PubMed ID: 16476934)
1. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial.
Huntington Study Group
Neurology; 2006 Feb; 66(3):366-72. PubMed ID: 16476934
[TBL] [Abstract][Full Text] [Related]
2. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators.
Frank S
BMC Neurol; 2009 Dec; 9():62. PubMed ID: 20021666
[TBL] [Abstract][Full Text] [Related]
3. The long-term effect of tetrabenazine in the management of Huntington disease.
Fasano A; Cadeddu F; Guidubaldi A; Piano C; Soleti F; Zinzi P; Bentivoglio AR
Clin Neuropharmacol; 2008; 31(6):313-8. PubMed ID: 19050408
[TBL] [Abstract][Full Text] [Related]
4. Short-term effects of tetrabenazine on chorea associated with Huntington's disease.
Kenney C; Hunter C; Davidson A; Jankovic J
Mov Disord; 2007 Jan; 22(1):10-3. PubMed ID: 17078062
[TBL] [Abstract][Full Text] [Related]
5. Tetrabenazine: for chorea associated with Huntington's disease.
Scott LJ
CNS Drugs; 2011 Dec; 25(12):1073-85. PubMed ID: 22133328
[TBL] [Abstract][Full Text] [Related]
6. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.
Chen JJ; Ondo WG; Dashtipour K; Swope DM
Clin Ther; 2012 Jul; 34(7):1487-504. PubMed ID: 22749259
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
Furr Stimming E; Claassen DO; Kayson E; Goldstein J; Mehanna R; Zhang H; Liang GS; Haubenberger D;
Lancet Neurol; 2023 Jun; 22(6):494-504. PubMed ID: 37210099
[TBL] [Abstract][Full Text] [Related]
8. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease.
Frank S; Ondo W; Fahn S; Hunter C; Oakes D; Plumb S; Marshall F; Shoulson I; Eberly S; Walker F; Factor S; Hunt V; Shinaman A; Jankovic J
Clin Neuropharmacol; 2008; 31(3):127-33. PubMed ID: 18520979
[TBL] [Abstract][Full Text] [Related]
9. Tetrabenazine treatment for Huntington's disease-associated chorea.
Ondo WG; Tintner R; Thomas M; Jankovic J
Clin Neuropharmacol; 2002; 25(6):300-2. PubMed ID: 12469001
[TBL] [Abstract][Full Text] [Related]
10. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders.
Kenney C; Hunter C; Jankovic J
Mov Disord; 2007 Jan; 22(2):193-7. PubMed ID: 17133512
[TBL] [Abstract][Full Text] [Related]
11. Tetrabenazine treatment in movement disorders.
Paleacu D; Giladi N; Moore O; Stern A; Honigman S; Badarny S
Clin Neuropharmacol; 2004; 27(5):230-3. PubMed ID: 15602104
[TBL] [Abstract][Full Text] [Related]
12. Treatment of chorea associated with Huntington's disease: focus on tetrabenazine.
Setter SM; Neumiller JJ; Dobbins EK; Wood L; Clark J; DuVall CA; Santiago A
Consult Pharm; 2009 Jul; 24(7):524-37. PubMed ID: 19689181
[TBL] [Abstract][Full Text] [Related]
13. Impact of tetrabenazine on gait and functional mobility in individuals with Huntington's disease.
Kegelmeyer DA; Kloos AD; Fritz NE; Fiumedora MM; White SE; Kostyk SK
J Neurol Sci; 2014 Dec; 347(1-2):219-23. PubMed ID: 25456459
[TBL] [Abstract][Full Text] [Related]
14. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial.
Savani AA; Login IS
Neurology; 2007 Mar; 68(10):797; author reply 797. PubMed ID: 17339599
[No Abstract] [Full Text] [Related]
15. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease.
Dean M; Sung VW
Drug Des Devel Ther; 2018; 12():313-319. PubMed ID: 29497277
[TBL] [Abstract][Full Text] [Related]
16. Management of Huntington's disease: role of tetrabenazine.
de Tommaso M; Serpino C; Sciruicchio V
Ther Clin Risk Manag; 2011; 7():123-9. PubMed ID: 21479143
[TBL] [Abstract][Full Text] [Related]
17. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.
; Frank S; Testa CM; Stamler D; Kayson E; Davis C; Edmondson MC; Kinel S; Leavitt B; Oakes D; O'Neill C; Vaughan C; Goldstein J; Herzog M; Snively V; Whaley J; Wong C; Suter G; Jankovic J; Jimenez-Shahed J; Hunter C; Claassen DO; Roman OC; Sung V; Smith J; Janicki S; Clouse R; Saint-Hilaire M; Hohler A; Turpin D; James RC; Rodriguez R; Rizer K; Anderson KE; Heller H; Carlson A; Criswell S; Racette BA; Revilla FJ; Nucifora F; Margolis RL; Ong M; Mendis T; Mendis N; Singer C; Quesada M; Paulsen JS; Brashers-Krug T; Miller A; Kerr J; Dubinsky RM; Gray C; Factor SA; Sperin E; Molho E; Eglow M; Evans S; Kumar R; Reeves C; Samii A; Chouinard S; Beland M; Scott BL; Hickey PT; Esmail S; Fung WL; Gibbons C; Qi L; Colcher A; Hackmyer C; McGarry A; Klos K; Gudesblatt M; Fafard L; Graffitti L; Schneider DP; Dhall R; Wojcieszek JM; LaFaver K; Duker A; Neefus E; Wilson-Perez H; Shprecher D; Wall P; Blindauer KA; Wheeler L; Boyd JT; Houston E; Farbman ES; Agarwal P; Eberly SW; Watts A; Tariot PN; Feigin A; Evans S; Beck C; Orme C; Edicola J; Christopher E
JAMA; 2016 Jul; 316(1):40-50. PubMed ID: 27380342
[TBL] [Abstract][Full Text] [Related]
18. [Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements].
Giménez-Roldán S; Mateo D
Neurologia; 1989 Oct; 4(8):282-7. PubMed ID: 2534679
[TBL] [Abstract][Full Text] [Related]
19. Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine.
Brusa L; Orlacchio A; Moschella V; Iani C; Bernardi G; Mercuri NB
Mov Disord; 2009 Jan; 24(1):126-9. PubMed ID: 19170197
[TBL] [Abstract][Full Text] [Related]
20. Deutetrabenazine: A Review in Chorea Associated with Huntington's Disease.
Heo YA; Scott LJ
Drugs; 2017 Nov; 77(17):1857-1864. PubMed ID: 29080203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
